In one paragraphArticle in Circulation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
3 authors.
Marion DelaunayDepartment of Medicine, Division of Cardiology and Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora.ORCID 0009-0003-1675-9046 Zegeye H JebessaDepartment of Medicine, Division of Cardiology and Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora.ORCID 0000-0003-1225-4959 Timothy A McKinseyDepartment of Medicine, Division of Cardiology and Consortium for Fibrosis Research & Translation, University of Colorado Anschutz Medical Campus, Aurora.ORCID 0000-0001-7778-4470 Funding
Regulation of Chromatin Signaling in Heart Failure by the BRD4 Bromodomain Protein.R01HL127240 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI MCKINSEY, TIMOTHY, SRIVASTAVA, DEEPAK · 2015 to 2022
$6.4MDeacetylase-Dependent Control of Diastolic Dysfunction and HFpEFR01HL147558 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI HOUSER, STEVEN R, MCKINSEY, TIMOTHY · 2019 to 2022
$3.1MRegulation of Cardiac Signaling by Class I Histone DeacetylasesR01HL116848 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI MCKINSEY, TIMOTHY · 2013 to 2021
$3.1MSmall molecule therapies targeting chromatin architecture in heart failureR01HL150225 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCKINSEY, TIMOTHY, VONDRISKA, THOMAS M. · 2020 to 2023
$2.9M15-PGDH-Mediated Eicosanoid Degradation in Cardiac Fibrosis and Heart FailureR01HL171711 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI Timothy McKinsey · 2024 to 2026
$1.6MTargeting HDAC6 to Modulate Titin Stiffness for Dilated Cardiomyopathy TherapyR43HL154959 · NHLBI · EIKONIZO THERAPEUTICS, INC. · PI SCHROEDER, FREDERICK ALBERT · 2020 to 2020
$300kNHLBI NIH HHS R01 HL116848NHLBI NIH HHS R01 HL127240NHLBI NIH HHS R01 HL147558NHLBI NIH HHS R01 HL150225NHLBI NIH HHS R01 HL171711NHLBI NIH HHS R43 HL154959
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Heart FailureAnimalsCyclophilinsHumansCyclophilinsEditorialsheart failureisomerismmyocardial infarctionventricular remodeling
Identifiers
PMID39265042
PMCPMC11649304
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390